Russell Investments Group Ltd. Lowers Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Russell Investments Group Ltd. lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 6.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 319,807 shares of the medical instruments supplier’s stock after selling 23,338 shares during the quarter. Russell Investments Group Ltd. owned 1.44% of LeMaitre Vascular worth $21,517,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Harbor Capital Advisors Inc. purchased a new position in LeMaitre Vascular in the 2nd quarter worth $26,000. Altshuler Shaham Ltd purchased a new position in LeMaitre Vascular in the 2nd quarter worth $29,000. Captrust Financial Advisors raised its position in LeMaitre Vascular by 555.3% in the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 522 shares during the period. FMR LLC raised its position in LeMaitre Vascular by 111.7% in the 1st quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 334 shares during the period. Finally, Pacer Advisors Inc. bought a new stake in LeMaitre Vascular in the 2nd quarter worth $39,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Up 1.2 %

Shares of LMAT opened at $53.76 on Tuesday. The firm’s 50-day moving average price is $52.09 and its 200-day moving average price is $58.75. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of 44.43, a PEG ratio of 2.94 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1-year low of $43.69 and a 1-year high of $68.67.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.33 EPS for the quarter, topping the consensus estimate of $0.31 by $0.02. LeMaitre Vascular had a net margin of 14.69% and a return on equity of 9.83%. The business had revenue of $47.40 million for the quarter, compared to analyst estimates of $47.58 million. During the same quarter in the previous year, the firm posted $0.25 earnings per share. LeMaitre Vascular’s quarterly revenue was up 21.5% on a year-over-year basis. On average, research analysts forecast that LeMaitre Vascular, Inc. will post 1.34 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 30th. Investors of record on Thursday, November 16th will be paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend is Wednesday, November 15th. LeMaitre Vascular’s payout ratio is currently 46.28%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and raised their price target for the stock from $63.00 to $67.00 in a report on Thursday, August 3rd. Lake Street Capital raised their price target on shares of LeMaitre Vascular from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Barrington Research raised their price target on shares of LeMaitre Vascular from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Wednesday, August 2nd. JMP Securities started coverage on shares of LeMaitre Vascular in a report on Monday, October 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Oppenheimer started coverage on shares of LeMaitre Vascular in a research note on Tuesday, September 5th. They set an “outperform” rating and a $70.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $67.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.